

## Spirify Pharma attending BIO Partnering Conference during JP Morgan week in January 2022

Naples, FL, December 12, 2021.

Spirify Pharma, Inc. ("Spirify"), a pharmaceutical company utilizing a platform approach for a class of proprietary modulators of D-Serine levels in the CNS, is announcing its participation in the the BIO Partnering Conference during JP Morgan week from January 10-14, 2022.

Spirify intends to bring potent fast-acting orally available candidate molecules into clinical development in CRPS, other forms of neuropathic pain, depression, neurodegenerative diseases, and others. The company will be represented by Alexander Kraus PhD, Chief Business Officer at Spirify Pharma. Spirify will be meeting with pharmaceutical companies and investors and is actively seeking for strategic partnerships, territorial licensing arrangements, and investment to advance and accelerate a pipeline of innovative drug candidates into the clinic.

### About Spirify Pharma, Inc.

Spirify Pharma, Inc. is a pharmaceutical company dedicated to transforming the way pain and depression are treated by developing novel therapeutics based on HNK derivative compounds. Spirify is based in Naples, Florida. More information can be found by visiting the Spirify website at [www.spirifypharma.com](http://www.spirifypharma.com).

### Spirify Contact:

Sigal Kremer-Tal, MD - CEO & Co-founder  
stal@spirifypharma.com

Alexander Kraus, PhD - CBO  
akraus@spirifypharma.com